• Medicago Inc., of Quebec City, said it successfully produced a rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using its plant-based manufacturing system. That achievement completes the first part of the firm's collaboration with Mitsubishi Tanabe Pharma Corp., of Osaka, Japan, toward the development of a rotavirus vaccine candidate.